SS-31 (elamipretide) , a mitochondria-targeted peptide that stabilizes cardiolipin to support energy production, became the first FDA-approved mitochondrial therapeutic in 2025, though only for the rare Barth syndrome, with the brain rationale still mechanistic and no cognitive trials
keep away from fire or flame
2017, Tenchov et al 2024) which can reduce an individuals quality of life and lead to complications that overburden the healthcare system (Aina et al 2021)
Still, one high-profile peptide enthusiast wants to make it easier to get peptides: Health Secretary Robert F
For people struggling with stubborn injuries, gut issues, or systemic inflammation, it represents a unique therapeutic option
GLP-1 medications are metabolized through proteolytic degradation, not through the liver's cytochrome P450 enzyme system